These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 21095486

  • 1. Modulation of CD20 antigen expression after rituximab treatment: a retrospective study in patients with chronic lymphocytic leukemia.
    D'Auria F, Guariglia R, Villani O, Mansueto G, Grieco V, Zonno A, Bianchino G, Di Giovannantonio L, Vita G, Musto P.
    Clin Ther; 2010 Oct; 32(11):1911-6. PubMed ID: 21095486
    [Abstract] [Full Text] [Related]

  • 2. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
    Maeshima AM, Taniguchi H, Fukuhara S, Morikawa N, Munakata W, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Tsuda H.
    Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
    [Abstract] [Full Text] [Related]

  • 3. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.
    Beum PV, Peek EM, Lindorfer MA, Beurskens FJ, Engelberts PJ, Parren PW, van de Winkel JG, Taylor RP.
    J Immunol; 2011 Sep 15; 187(6):3438-47. PubMed ID: 21841127
    [Abstract] [Full Text] [Related]

  • 4. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma.
    Horvat M, Kloboves Prevodnik V, Lavrencak J, Jezersek Novakovic B.
    Oncol Rep; 2010 Oct 15; 24(4):1101-7. PubMed ID: 20811695
    [Abstract] [Full Text] [Related]

  • 5. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients.
    Tam CS, Otero-Palacios J, Abruzzo LV, Jorgensen JL, Ferrajoli A, Wierda WG, Lerner S, O'Brien S, Keating MJ.
    Br J Haematol; 2008 Apr 15; 141(1):36-40. PubMed ID: 18324964
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.
    Patz M, Isaeva P, Forcob N, Müller B, Frenzel LP, Wendtner CM, Klein C, Umana P, Hallek M, Krause G.
    Br J Haematol; 2011 Feb 15; 152(3):295-306. PubMed ID: 21155758
    [Abstract] [Full Text] [Related]

  • 7. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E.
    Haematologica; 2002 Jan 15; 87(1):33-43. PubMed ID: 11801463
    [Abstract] [Full Text] [Related]

  • 8. Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells.
    Mankaï A, Bordron A, Renaudineau Y, Martins-Carvalho C, Takahashi S, Ghedira I, Berthou C, Youinou P.
    Cancer Res; 2008 Sep 15; 68(18):7512-9. PubMed ID: 18794139
    [Abstract] [Full Text] [Related]

  • 9. Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1.
    Mankaï A, Buhé V, Hammadi M, Youinou P, Ghedira I, Berthou C, Bordron A.
    Ann N Y Acad Sci; 2009 Sep 15; 1173():721-8. PubMed ID: 19758221
    [Abstract] [Full Text] [Related]

  • 10. Antigen modulation followed by quantitative flow cytometry of B-chronic lymphocytic leukemia cells after treatment.
    Kusenda J, Babusíková O.
    Neoplasma; 2004 Sep 15; 51(2):97-102. PubMed ID: 15190418
    [Abstract] [Full Text] [Related]

  • 11. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas.
    Beum PV, Kennedy AD, Taylor RP.
    J Immunol Methods; 2004 Jun 15; 289(1-2):97-109. PubMed ID: 15251416
    [Abstract] [Full Text] [Related]

  • 12. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia.
    Huh YO, Keating MJ, Saffer HL, Jilani I, Lerner S, Albitar M.
    Am J Clin Pathol; 2001 Sep 15; 116(3):437-43. PubMed ID: 11554173
    [Abstract] [Full Text] [Related]

  • 13. Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia.
    Perz J, Topaly J, Fruehauf S, Hensel M, Ho AD.
    Leuk Lymphoma; 2002 Jan 15; 43(1):149-51. PubMed ID: 11908720
    [Abstract] [Full Text] [Related]

  • 14. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
    Milani C, Castillo J.
    Curr Opin Mol Ther; 2009 Apr 15; 11(2):200-7. PubMed ID: 19330725
    [Abstract] [Full Text] [Related]

  • 15. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL.
    Klepfish A, Gilles L, Ioannis K, Rachmilewitz EA, Schattner A.
    Ann N Y Acad Sci; 2009 Sep 15; 1173():865-73. PubMed ID: 19758239
    [Abstract] [Full Text] [Related]

  • 16. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco FA, Minnie Pearl Cancer Research Network.
    J Clin Oncol; 2003 May 01; 21(9):1746-51. PubMed ID: 12721250
    [Abstract] [Full Text] [Related]

  • 17. Bone marrow stromal mesenchymal cells induce down regulation of CD20 expression on B-CLL: implications for rituximab resistance in CLL.
    Marquez ME, Hernández-Uzcátegui O, Cornejo A, Vargas P, Da Costa O.
    Br J Haematol; 2015 Apr 01; 169(2):211-8. PubMed ID: 25612644
    [Abstract] [Full Text] [Related]

  • 18. [Density expression of the CD20 antigen on population of tumor cells in patients with chronic B-lymphocyte lymphoproliferative diseases].
    Suková V, Klabusay M, Coupek P, Brychtová Y, Doubek M, Mayer J.
    Cas Lek Cesk; 2006 Apr 01; 145(9):712-6; discussion 716-7. PubMed ID: 17091727
    [Abstract] [Full Text] [Related]

  • 19. Rituximab in chronic lymphocytic leukemia.
    Jaglowski SM, Byrd JC.
    Semin Hematol; 2010 Apr 01; 47(2):156-69. PubMed ID: 20350663
    [Abstract] [Full Text] [Related]

  • 20. 4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia.
    Buechele C, Baessler T, Schmiedel BJ, Schumacher CE, Grosse-Hovest L, Rittig K, Salih HR.
    Eur J Immunol; 2012 Mar 01; 42(3):737-48. PubMed ID: 22144129
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.